<i>HER2</i> Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29496760.
- Also identified by DOI 10.1158/1078-0432.CCR-18-0198.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<i>HER2</i>-deregulated non-small cell lung cancer is an orphan of any specific therapy, probably because of lack of both accurate patient selection and effective drugs. Recent evidence suggests that osimertinib could be effective in <i>HER2</i>-amplified or mutated lung cancer as a single agent or in combination. <i>Clin Cancer Res; 24(11); 2470-2. ©2018 AACR</i><i>See related article by Liu et al., p. 2594</i>.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms